Emerging role of aromatase inhibitors in the adjuvant setting

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 4 SUPPL. 1, 2003, Pages

  Goss, Paul E ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Anastrozole; Aromatase inhibitors; Letrozole Exemestane; Quality of life; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BONE METABOLISM; BREAST CANCER; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; ENDOMETRIUM CANCER; HOT FLUSH; HUMAN; LIPID METABOLISM; QUALITY OF LIFE; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINA DISEASE; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BONE REMODELING; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; ENZYME INHIBITORS; HUMANS; NEOADJUVANT THERAPY; NITRILES; QUALITY OF LIFE; TAMOXIFEN; TRIAZOLES;

EID: 0041589588     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200308001-00005     Document Type: Review

References (28)

1. Goss PE. Risks versus benefits in the clinical application of aromatase inhibitors. Endocrin Relat Cancer 1999;6:325-32.
2. Santen RJ, Harvey HA. Use of aromatase inhibitors in breast carcinoma. Endocrin Relat Cancer 1999;6:75-92.
3. Buzdar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 2001;7:2620-35.
4. Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001;19:881-94.
5. Pritchard KI. Endocrine therapy for breast cancer. Oncology (Huntingt) 2000;14:483-92; discussion 93, 97-98.
6. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
7. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684-90.
8. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
9. Holli K, Valavaara R, Blanco G, et al. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. J Clin Oncol 2000;18:3487-94.
10. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-42.
11. Peto R. Five years of tamoxifen - or more? J Natl Cancer Inst 1996;88:1791-3.
12. Chang J, Powles TJ, Allred DC, et al. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res 2000;6:616-21.
13. Bonneterre J, Thürlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748-57.
14. Baum M. Use of aromatase inhibitors in the adjuvant treatment of breast cancer. Endocrin Relat Cancer 1999;6:231-4.
15. Mauriac L, Debled M, Durand M, et al. Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women. Ann Oncol 2002;13:293-8.
16. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001;12: 1527-32.
17. Heshmati HM, Khosla S, Robins SP, et al. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 2002;17:172-8.
18. Harper-Wynne C, Ross G, Sacks N, et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 2002;11:614-21.
19. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-606.
20. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9.
21. Elisaf MS, Bairaktari ET, Nicolaides C, et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 2001;37:1510-3.
22. Goss PE. Preliminary data from ongoing adjuvant aromatase inhibitor trials. Clin Cancer Res 2001;7:4397s-401s; discussion 411s-412s.
23. Mamounas EP. Adjuvant exemestane therapy after 5 years of tamoxifen: rationale for the NSABP B-33 trial. Oncology (Huntingt) 2001;15:35-9.
24. Ragaz J. Adjuvant trials of aromatase inhibitors: determining the future landscape of adjuvant endocrine therapy. J Steroid Biochem Mol Biol 2001;79:133-41.
25. Baum M. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in post-menopausal (PM) women [Abstract 8]. Breast Cancer Res Treat 2001;69:210.
26. Bryant J, Fisher B, Dignam J. Duration of adjuvant tamoxifen therapy. J Natl Cancer Inst Monogr 2001;56-61.
27. Santen RJ, Yue W, Naftolin F, et al. The potential of aromatase inhibitors in breast cancer prevention. Endocrin Relat Cancer 1999;6:235-43.
28. Stephenson J. Estrogen as a carcinogen. JAMA 2001;285:284.